Is It Time To Reassess Labcorp (LH) After Its Recent Share Price Strength?

Simply Wall St.

Apr 16

Wondering if Labcorp Holdings at around US$268.87 is still good value or starting to look fully priced, especially after a strong run? This article breaks that question down in plain terms. The stock ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2627318622"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627318622\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627318622?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","is_english":true,"pubTime":"2026-04-16 00:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627318622","market":"us","top_or_hot":-1,"title":"Is It Time To Reassess Labcorp (LH) After Its Recent Share Price Strength?","media":"Simply Wall St.","content":"<div>\n<p>Wondering if Labcorp Holdings at around US$268.87 is still good value or starting to look fully priced, especially after a strong run? This article breaks that question down in plain terms. The stock ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/is-it-time-to-reassess-labcorp-lh-after-its-recent-share-pri\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reassess Labcorp (LH) After Its Recent Share Price Strength?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reassess Labcorp (LH) After Its Recent Share Price Strength?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-16 00:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/is-it-time-to-reassess-labcorp-lh-after-its-recent-share-pri><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering if Labcorp Holdings at around US$268.87 is still good value or starting to look fully priced, especially after a strong run? This article breaks that question down in plain terms. The stock ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/is-it-time-to-reassess-labcorp-lh-after-its-recent-share-pri\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1059921491.USD","symbol_name":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/is-it-time-to-reassess-labcorp-lh-after-its-recent-share-pri","article_id":"2627318622","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/is-it-time-to-reassess-labcorp-lh-after-its-recent-share-pri","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627318622","pubTimestamp":1776269387,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering if Labcorp Holdings at around US$268.87 is still good value or starting to look fully priced, especially after a strong run? This article breaks that question down in plain terms.\nThe stock has recently posted a 6.8% return year to date and 20.2% over the last year, with shorter term moves of 1.9% over 30 days and a slight 0.1% decline over 7 days that may have caught your attention.\nRecent news coverage has focused on Labcorp's position within the broader healthcare sector,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LH":"徕博科","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4550":"红杉资本持仓","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0251142724.SGD":"Fidelity America A-SGD","BK4196":"保健护理服务","BK4588":"碎股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4585":"ETF&股票定投概念","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC"},"translate_title":"Labcorp(LH)近期股价走强后，是时候重新评估其股价了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":1.5,"DCF":1},"content_text":"Wondering if Labcorp Holdings at around US$268.87 is still good value or starting to look fully priced, especially after a strong run? This article breaks that question down in plain terms. The stock has recently posted a 6.8% return year to date and 20.2% over the last year, with shorter term moves of 1.9% over 30 days and a slight 0.1% decline over 7 days that may have caught your attention. Recent news coverage has focused on Labcorp's position within the broader healthcare sector, including how its diagnostics and laboratory services business fits into changing demand patterns and healthcare spending themes. This context helps frame whether the recent share price gains are being driven more by sentiment, expectations about the business, or a mix of both. Labcorp currently has a valuation score of 4 out of 6. Next comes a closer look at what different valuation approaches say about the stock today, along with a final section on a more rounded way to think about value beyond any single model.  Labcorp Holdings delivered 20.2% returns over the last year. See how this stacks up to the rest of the Healthcare industry. AdvertisementApproach 1: Labcorp Holdings Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes the cash Labcorp Holdings is expected to generate in the future and discounts those projected cash flows back into today’s dollars to estimate what the entire business might be worth now. For Labcorp, the latest twelve month Free Cash Flow is about $1.15b. Using a 2 Stage Free Cash Flow to Equity model, analysts provide specific estimates out to 2029, with Simply Wall St then extrapolating further. Within that framework, projected Free Cash Flow for 2029 is $1.73b, and discounted ten year projections range from about $1.20b to $1.32b per year in today’s terms. When those cash flows are aggregated and adjusted, the DCF model indicates an estimated intrinsic value of about $562.05 per share, compared with the recent share price of roughly $268.87. That difference suggests the stock is around 52.2% below this particular estimate of fair value, which is a substantial variation for investors to consider. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Labcorp Holdings is undervalued by 52.2%. Track this in your watchlist or portfolio, or discover 57 more high quality undervalued stocks. LH Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Labcorp Holdings. Approach 2: Labcorp Holdings Price vs Earnings For a profitable business like Labcorp Holdings, the P/E ratio is a useful way to see how much investors are currently willing to pay for each dollar of earnings. It links directly to what the company earns today, which many investors use as a reference point when assessing what feels like a reasonable price. What counts as a “normal” P/E tends to move around with growth expectations and risk. Higher expected earnings growth or a business profile that investors see as relatively resilient can support a higher multiple, while slower growth or higher perceived risk usually points to a lower one. Labcorp is trading on a P/E of 25.21x. That sits above the broader Healthcare sector average of about 22.62x and below the peer group average of 35.87x. Simply Wall St’s Fair Ratio for Labcorp is 28.57x, which is a proprietary estimate of the P/E that might be reasonable given factors such as earnings growth, profit margins, industry characteristics, market cap and company specific risks. The Fair Ratio can be more informative than a simple peer or sector comparison because it adjusts for these business specific drivers rather than assuming all companies deserve similar multiples. With Labcorp’s current P/E at 25.21x versus a Fair Ratio of 28.57x, the stock screens as undervalued on this metric. Result: UNDERVALUED NYSE:LH P/E Ratio as at Apr 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies. Upgrade Your Decision Making: Choose your Labcorp Holdings Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as a simple way for you to write the story behind your numbers, link Labcorp Holdings’ business drivers to a forecast for revenue, earnings and margins, and then connect that forecast to a Fair Value that you can compare with the current share price on Simply Wall St’s Community page. Narratives are used by millions of investors and refresh automatically when new earnings or news arrive. For example, one investor might build a bullish Labcorp view around expanded cancer and Alzheimer’s testing, higher earnings expectations of about $1.4b and a Fair Value closer to the higher analyst target of US$342. Another might focus on risks like tariffs, regulatory changes and competitive pressure, keep earnings closer to $888.7m and anchor on a Fair Value nearer the lower analyst target of US$260. You can see both perspectives side by side to help decide whether Labcorp looks closer to a buy, a hold or a sell for your own approach. Do you think there's more to the story for Labcorp Holdings? Head over to our Community to see what others are saying! NYSE:LH 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}